In the majority of the world, the standard of care for newly diagnosed Hodgkin lymphoma has not changed in more than three decades, and is based on the globally recognized ABVD
regimen of four chemotherapy drugs.
At present, 4-6 cycles of ABVD
chemotherapy protocol are usually used for stage I-II A/B unfavorable disease, because it highly effective and has a favorable toxicity profile.
Many oncologists do not refer Hodgkin's lymphoma patients on the assumption that all will be fine after ABVD
Approximately 400 patients with non-bulky (small tumor size) clinical stage I-IIA HL were stratified into low- and high-risk groups and randomized into two treatment arms: those who received ABVD
and those who received extended-field RT (with or without ABVD
Rates of acute toxicity were higher with BEACOPP versus ABVD
BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD
or equivalent regimens.
Previously the MOPP(mechlorethamine, vincristine, procarbazine, prednisolone), COPP (cyclophosphamide, vincristine, procarbazine, prednisolone), and MOPP-ABV (alternating cycles of mechlorethamine, vincristine, procarbazine, prednisolone, and doxorubicin, bleomycin, vinblastin, and dacarbazine) regimens were frequently administered, whereas ABVD
(doxorubicin, bleomycin, vinblastin, and dacarbazine) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) chemotherapy regimens are currently more popular.
Dose-Escalation With BEACOPP Escalated Is Superior to ABVD
in the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial [Abstract #765]
Four cycles of ABVD
and 30 Gy were associated with higher rates of acute toxicities.
After surgery, the patient received 4 cycles of ABVD
(doxorubicin, bleomycin, vinblastine, and dacarbazine).
Chemotherapy of advanced Hodgkin's disease treated with MOPP, ABVD
, or MOPP alternating with ABVD
In the phase I trial, newly diagnosed patients received ADCETRIS concomitantly with either ABVD
(Adriamycin, bleomycin, vinblastine and dacarbazine) or AVD, which removes bleomycin from the regimen.